BRIEF published on 07/24/2026 at 10:01, 13 days 13 hours ago BlackRock Inc. reduces its stake in IPSEN SA Voting Rights Actions BlackRock Threshold Crossing Ipsen SA
BRIEF published on 07/24/2026 at 07:05, 13 days 16 hours ago Update on Ipsen's Phase III BOLD Trial in Biliary Atresia Clinical Research Biliary Atresia Phase III BOLD Trial Odevixibat Liver Transplantation
PRESS RELEASE published on 07/24/2026 at 07:00, 13 days 16 hours ago Ipsen provides update on Phase III BOLD trial in biliary atresia Ipsen's Phase III BOLD trial for biliary atresia did not meet primary endpoint. Bylvay safety profile confirmed. Insights gained will aid future research and patient care Ipsen Biliary Atresia Phase III BOLD Trial Bylvay Pediatric Liver Transplant
BRIEF published on 07/09/2026 at 07:05, 28 days 16 hours ago Dysport® Achieves Milestone in Migraine Phase III Trials Phase III Trials Dysport Episodic Migraine Chronic Migraine Botulinum Toxin
BRIEF published on 07/09/2026 at 07:05, 28 days 16 hours ago Positive Phase III Results for Dysport® in the Treatment of Migraine Phase III Dysport Episodic Migraine Chronic Migraine Botulinum Toxin
PRESS RELEASE published on 07/09/2026 at 07:00, 28 days 16 hours ago Dysport® is the first botulinum toxin to achieve positive topline Phase III results in both episodic and chronic migraine. Dysport® achieves positive topline Phase III results in both episodic and chronic migraine, marking a significant advancement in migraine treatment Prevention Dysport® Botulinum Toxin Phase III Results Migraine
BRIEF published on 07/06/2026 at 12:02, 1 month ago BlackRock's stake in IPSEN SA fluctuates at the 5% threshold. Share Capital Voting Rights BlackRock Threshold Crossing Ipsen SA
BRIEF published on 06/29/2026 at 07:05, 1 month 7 days ago Ipsen to Acquire Kartos Therapeutics, Enhancing Hemato-Oncology Portfolio Hemato-oncology Ipsen Acquisition Ruxolitinib Myelofibrosis Navtemadlin
PRESS RELEASE published on 06/29/2026 at 07:00, 1 month 7 days ago Ipsen to acquire Kartos Therapeutics, expanding hemato-oncology late-stage pipeline Ipsen acquires Kartos Therapeutics, adding navtemadlin, a late-stage rare blood cancer asset in Phase III, to expand its Oncology portfolio. Top-line data from Phase III trial expected in 2027 Phase III Ipsen Hemato-oncology Navtemadlin Kartos Therapeutics
BRIEF published on 05/18/2026 at 07:05, 2 months 19 days ago Ipsen Initiates New Share Buy-back Program Share Buy-back Shareholder Value Investment Strategy Employee Share Plans Euronext: IPN
Published on 08/06/2026 at 23:15, 6 minutes ago LNG Energy Group Announces Issuance of Second Partial Revocation Order and Further Details on Private Placement Financing
Published on 08/06/2026 at 22:15, 1 hour 6 minutes ago Biomind Labs Announces Listing on the Canadian Securities Exchange and the Delisting From the Cboe Canada
Published on 08/06/2026 at 22:05, 1 hour 16 minutes ago Innodata Reports Record Second Quarter 2026 Results
Published on 08/06/2026 at 22:00, 1 hour 21 minutes ago Gold Terra Announces Closing of Second Tranche of the C$10.8M LIFE
Published on 08/06/2026 at 15:00, 8 hours 21 minutes ago Norsemont Strategically Expands Choquelimpie Land Package To 9,048 Hectares
Published on 08/06/2026 at 22:15, 1 hour 6 minutes ago BIRKENSTOCK SEEKS TO FILL VACANCY IN THE BOARD OF DIRECTORS WITH AN INDEPENDENT DIRECTOR, FOLLOWING ALEXANDRE ARNAULT'S RESIGNATION DUE TO PROFESSIONAL COMMITTMENTS
Published on 08/06/2026 at 21:45, 1 hour 35 minutes ago FP Markets Analysis: Japanese Yen at a Crossroads as Markets Weigh Next Move
Published on 08/06/2026 at 19:05, 4 hours 15 minutes ago Cision Wins 2026 MarTech Breakthrough Awards for Social Listening, Press Release Distribution, and AEO
Published on 08/06/2026 at 18:24, 4 hours 56 minutes ago EQS-Adhoc: Allgeier SE: Allgeier Increases Revenue by 10 Percent in the First Half of 2026 and Confirms Its Guidance for 2026
Published on 08/06/2026 at 18:26, 4 hours 55 minutes ago Air Liquide voting rights as of July 31st 2026
Published on 08/06/2026 at 17:45, 5 hours 36 minutes ago Declaration of voting rights at the end of July 2026
Published on 08/06/2026 at 17:35, 5 hours 46 minutes ago Groupe des Assurances du Crédit Mutuel (GACM)’s Solvency II ratio was 227% as of June 30, 2026
Published on 08/06/2026 at 17:35, 5 hours 46 minutes ago Availability of the financial statements of Groupe des Assurances du Crédit Mutuel for the first half of 2026
